Catalent (CTLT) Misses Q4 EPS by 1c, FY17 Revenue Guidance Tops Views at Mid-Point
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Catalent, Inc. Reports Fourth Quarter and Fiscal Year 2016 Results
August 29, 2016 4:15 PM EDTQ4'16 revenue $532.2 million increased 6% in constant currency from the prior year period FY'16 revenue of $1.85 billion increased 6% in constant currency from the prior year period Catalent's proprietary OptiShell softgel technology has been selected for use in OPKO Health's NDA for RAYALDEE® and has been approved by the U.S. FDA Announced the launch of our FastChain service, for greater speed, flexibility and efficiency in the management and distribution of global clinical trial supplies... More
